Infection control - 07/01/2021 Gene accordions as potential markers for pathogenic properties Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.https:////www.gesundheitsindustrie-bw.de:443/en/article/news/gene-accordions-potential-markers-pathogenic-properties
Lab-on-a-chip - 11/11/2020 Microfluidic platform for the best possible cancer therapy Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.https:////www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
Atriva Therapeutics - 21/10/2020 COVID-19 pioneer drug in Phase II clinical trial – with double the power The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…https:////www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
Press release - 01/09/2020 Strengthening the immune system with small molecules Infections pose an increasing risk to hospitalized patients. In collaboration with a number of partners, the Fraunhofer IGB has developed a new therapeutic approach as part of the InnateFun project. Their strategy is to improve cells’ ability to defend themselves against harmful microorganisms by acting on their immune receptors. The researchers’ work on this therapeutic approach has reached the animal model stage. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/strengthening-immune-system-small-molecules
Press release - 13/05/2020 Drug counterfeiters use fear of corona epidemic Falsified chloroquine tablets identified in Africa - University of Tübingen supports local pharmacists in the analysis.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/arzneimittelfaelscher-nutzen-angst-vor-corona-epidemie
Article - 20/01/2020 Brain tumour patients could benefit from heavy ion therapy Glioblastoma is a malignant brain tumour. It does not respond anywhere near as well to conventional forms of therapy than other tumours because it contains particularly resistant cancer cells. Scientists at the Heidelberg Ion Beam Therapy Center (HIT) at Heidelberg University Hospital and the German Cancer Research Center have shown that heavy ion therapy is effective against these cells.https:////www.gesundheitsindustrie-bw.de/en/article/news/Brain-tumour-patients-could-benefit-from-heavy-ion-therapy
Dossier - 06/12/2019 Microbiome: human health is closely connected with our microbial communities People have 1.3 times more microorganisms than body cells. This microbial community influences how we digest our food, how active our immune system is, as well as whether we tend to be more anxious or curious. A number of diseases have also been shown to be associated with a disturbed microbiome. Researchers still have a long way to go before the knowledge acquired can be used for developing therapies.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/microbiome-human-health-closely-connected-with-microbial-communities
Article - 05/08/2019 The answer to antibiotic resistance may lie in the microbiome Globally, increasing numbers of bacteria are becoming resistant to common antibiotics. Moreover, many reserve group antibiotics are no longer effective for infections caused by multidrug-resistant pathogens. Researchers in an excellence cluster at the University of Tübingen are investigating an alternative approach to combating bacterial infections. Their goal is to specifically influence the microbiome, the human microbial community.https:////www.gesundheitsindustrie-bw.de/en/article/news/answer-to-antibiotic-resistance-may-lie-in-the-microbiome
Freiburg im Breisgau - 04/06/2019 Spindiag’s continued road to success: Expansion of Series A with an additional 4 million euros for market entry Spindiag, a young medtech company in the German state of Baden-Württemberg, announced today the expanded financing of its first Series A. Based on a proprietary microfluidic technology first researched at the company’s mother institute Hahn-Schickard, Spindiag is developing a sustainable platform to diagnose infections and, as a first product, a rapid test for multidrug-resistant bacteria.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/spindiags-continued-road-to-success-expansion-of-series-a-with-an-additional-4-million-euros-for-market-entry
New edition - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/tumour-metastasis
Article - 16/04/2019 Tumour monitoring using liquid biopsy Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.https:////www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https:////www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Press release - 10/12/2018 High distinction for stem cell researcher Andreas Trumpp This year's State Research Prize of Baden-Württemberg awarded for outstanding achievements in applied research goes to Andreas Trumpp from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM). Theresia Bauer, State Minister of Science, Research and the Arts, presented the award, which carries a monetary prize of €100.000, at a festive ceremony on December 10, 2018.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/high-distinction-for-stem-cell-researcher-andreas-trumpp
Press release - 03/12/2018 SpinDiag closes second financing round of EUR 3.0 million (USD 3.4 million) to complete product development of its point-of-care screening system for antibiotic-resistant bacteria One year after its seed financing, SpinDiag GmbH closes a second financing round of EUR 3 million (USD 3.4 million) as planned. The financing will enable SpinDiag to complete the product development of its first product for screening for antibiotic-resistant bacteria and to start clinical trials. This will pave the way for regulatory approval in the EU.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/spindiag-closes-second-financing-round-of-eur-30-million-usd-34-million-to-complete-product-development-of-its-point-of-care-scr
Press release - 27/09/2018 Three new Clusters of Excellence for Tübingen University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-clusters-of-excellence-for-tuebingen
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Funding Future Insight Prize Funding programme, Funded by: Merck KGaA, Submission deadline: 31/12/2020 https:////www.gesundheitsindustrie-bw.de/en/database/funding/future-insight-prize
Article - 23/05/2018 Bacteriophages as alternatives to antibiotics Multidrug-resistant bacteria are resistant to many existing antibiotics and can be difficult to treat. There are increasing numbers of them worldwide. Although novel antibiotics are being developed, there are far too few of them to tackle the rise of multidrug-resistant bacteria. In Eastern Europe, doctors have been treating bacterial infections with viruses that infect bacteria, so-called bacteriophages, for almost 100 years.https:////www.gesundheitsindustrie-bw.de/en/article/news/bacteriophages-as-alternatives-to-antibiotics
Article - 25/04/2018 Resistance, immunity and malaria vaccination People who have survived a malaria infection often develop immunity to the disease. International malaria research is aimed at exploiting a person's natural immunity in order to treat malaria effectively and avoid resistance to previously effective drugs. These new approaches also raise hopes that one day countries at high risk of malaria may be able to eradicate the devastating disease. https:////www.gesundheitsindustrie-bw.de/en/article/news/resistance-immunity-and-malaria-vaccination
Press release - 03/04/2018 Double success for Heidelberg stem cell researchers Two awards at once, both carrying high monetary prizes, go to young researchers from the Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM) at the German Cancer Research Center (DKFZ): Simon Raffel will receive the 2018 Walter Schulz Prize. Simon Haas will share the 2018 Otto Schmeil Prize with his colleague Lars Velten from EMBL. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/double-success-for-heidelberg-stem-cell-researchers
Article - 20/02/2018 New strategies against malaria Malaria, which is a mosquito-borne disease caused by Plasmodium parasites, is still one of the worst infectious human diseases. The parasites have developed resistance against previously effective drugs and new strategies to combat malaria are urgently needed.https:////www.gesundheitsindustrie-bw.de/en/article/news/new-strategies-against-malaria
Article - 18/01/2018 Medications that target metastasing tumours Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.https:////www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
Article - 11/12/2017 KDM4 – an efficient target for the therapy of triple-negative breast cancer While breast cancer survival has clearly improved in recent years, women with triple-negative breast cancer have benefitted very little from progress in cancer medicine. Targeted therapies aimed at inhibiting epigenetic regulators might offer a potential new option for the treatment of breast cancer. Prof. Dr. Roland Schüle and Dr. Jochen Maurer have discovered an epigenetic enzyme called KDM4 and come up with a new cell model that significantly…https:////www.gesundheitsindustrie-bw.de/en/article/news/kdm4-an-efficient-target-for-the-therapy-of-triple-negative-breast-cancer
Article - 27/11/2017 Antimicrobial layer expected to fight hospital acquired infections Infections caused by bacteria that contaminate the surface of medical devices such as catheters and wound dressings are not that rare and can even be life-threatening. However, at present there is no really effective way to keep these products germ-free until they are used. Scientists at the University of Freiburg have now developed a surface coating that reliably kills bacteria, but is harmless to human cells.https:////www.gesundheitsindustrie-bw.de/en/article/news/antimicrobial-layer-expected-to-fight-hospital-acquired-infections
Article - 28/08/2017 SpinDiag GmbH – rapid test makes it difficult for pathogens Antibiotic-resistant pathogens are becoming an increasing problem, especially in hospitals. Infected patients must be isolated as soon as possible. However, appropriate methods for testing patients upon admission to hospital and isolating them if necessary are still lacking. A young biotechnology company from Baden-Württemberg called SpinDiag GmbH has developed a cost-effective method for the rapid testing of microbial resistance in normal…https:////www.gesundheitsindustrie-bw.de/en/article/news/spindiag-gmbh-rapid-test-makes-it-difficult-for-pathogens